Drug susceptibility testing of Mycobacterium tuberculosis to fluoroquinolones: First experience with a quality control panel in the Nordic-Baltic collaboration

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 9, 2003, Pages 899-902

  Johansen, Isik S ^a   Larsen, A R ^a   Sandven, P ^b   Petrini, B ^c   Soini, H ^d   Levina, K ^e   Sosnovskaja, A ^f   Skenders, G ^g   Hoffner, S ^h  

^a STATENS SERUM INSTITUT   (Denmark)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c KAROLINSKA INSTITUTE   (Sweden)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e Kivimae Hospital   (Estonia)

^f Natl TB Reference Laboratory   (Lithuania)

^g State Ctr of TB and Lung Diseases   (Latvia)

^h SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

MDR TB; Quality assurance; Second line drugs

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; DRUG SENSITIVITY; GYRA GENE; HUMAN; LABORATORY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; QUALITY CONTROL; SEQUENCE ANALYSIS;

ANTITUBERCULAR AGENTS; BALTIC STATES; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; FALSE POSITIVE REACTIONS; FLUOROQUINOLONES; HUMANS; INTERNATIONAL COOPERATION; LABORATORIES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NORWAY; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SWEDEN; TUBERCULOSIS, PULMONARY;

EID: 0141857651     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Pablos-Mendez A, Raviglione M C, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998; 338: 1641-1649.
2. Espinal M A, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344: 1294-1303.
3. World Health Organization. Guidelines for establishing DOTS-PLUS pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). Geneva: WHO, 2000.
4. Laszlo A, Rahman M, Raviglione M, Bustreo F. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis 1997; 1: 231-238.
5. Geerligs W A, van Altena R, de Lange W C M, van Soolingen D, van der Werf T S. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4: 758-764.
6. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
7. Inderlied C B, Salfinger M. Antimicrobial agents and susceptibility tests: Mycobacterium. In: Murray P R, Baron E J, Pfaller M A, Tenover F C, Yolken R H, eds. Manual of Clinical Microbiology. 6th ed. Washington: ASM, 1995: pp 1385-1404.
8. Pfyffer G E, Bonato D A, Ebrahimzadeh A, et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37: 3179-3186.
9. Siddiqi S H. BACTEC 460 TB SYSTEM. Product and Procedure Manual. Sparks, MD: Becton Dickinson Microbiology Systems, 1996.
10. Heifets L B, Lindholm-Levy P J. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle 1987; 68: 267-276.
11. Chen C H, Shih J F, Lindholm-Levy P J, Heifets L B. Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan. Am Rev Respir Dis 1989; 140: 987-989.
12. Hoffner S E, Gezelius L, Olsson-Liljequist B. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997; 40: 885-888.
13. Takiff H E, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis GyrA and GyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773-780.
14. Gorzynski E A, Gutman S I, Allea W. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob Agents Chemother 1989; 33: 591-592.
15. World Health Organization. Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOTS-PLUS. Geneva: WHO, 2001.
16. Kocagoz T, Hackbarth C J, Unsal I, Rosenberg E Y, Nikaido H, Chambers H F. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996; 40: 1768-1774.
17. Migliori G B, Ambrosetti M, Fattorini L, et al. Surveillance of anti-tuberculosis drug resistance: results of the 1998/1999 proficiency testing in Italy. SMIRA (Italian Multicentre Study on Antituberculosis Drug Resistance) Study Group. Int J Tuberc Lung Dis 2000; 4: 940-946.
18. Laszlo A, Rahman M, Espinal M, Raviglione, M. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD supranational reference laboratory network: five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis 2002; 6: 748-756.